Clinical Trials Logo

Respiratory Distress Syndrome clinical trials

View clinical trials related to Respiratory Distress Syndrome.

Filter by:

NCT ID: NCT06292338 Not yet recruiting - Clinical trials for Neonatal Respiratory Distress

Lung Sonar in Neonatal Respiratory Disorders

Start date: May 1, 2024
Phase:
Study type: Observational

This study aimed to determine the value of chest ultrasonography in comparison to other tools as chest x-ray and ABG in diagnosis and follow up of neonates with respiratory disorders.

NCT ID: NCT06278675 Not yet recruiting - Sepsis Clinical Trials

Multiple Study of Electroaccpuncture in ARDS

Start date: May 10, 2024
Phase: N/A
Study type: Interventional

In order to clarify the clinical efficacy of electroacupuncture on inhibiting systemic inflammatory response, improving respiratory mechanics parameters and prognosis in patients with sepsis-related ARDS.

NCT ID: NCT06276569 Not yet recruiting - Cardiac Disease Clinical Trials

Efficacy and Safety of Sivelestat in Preventing Postoperative Acute Respiratory Distress Syndrome After Cardiac Surgery :a Single Centre Random Control Trial.

Start date: February 18, 2024
Phase: Phase 3
Study type: Interventional

The aim of this study is to assess the effectiveness and safety of sivelestat sodium in preventing acute respiratory distress syndrome (ARDS) following cardiac surgery, with the objective of providing evidence-based support for its clinical application.

NCT ID: NCT06254313 Not yet recruiting - Influenza Clinical Trials

The Role of Cxcr4Hi neutrOPhils in InflueNza

CHOPIN
Start date: September 2024
Phase:
Study type: Observational

Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research. Especially, there is no therapeutic strategy targeting the dysregulated host response. CXCR4-expressing neutrophils seem to be involved in the rupture of host resistance. The aim of this study is thus to compare the percentage of blood CXCR4-expressing neutrophils between influenza survivors and non-survivors.

NCT ID: NCT06250348 Not yet recruiting - ARDS, Human Clinical Trials

Exhaled Nitric Oxide : Biomarker of Acute Respiratory Distress Syndrome

ENOBARDS
Start date: February 2024
Phase:
Study type: Observational

The aim of the study is to see if endogenous exhaled Nitric Oxyde (eNO) concentrations measured are significantly higher in ARDS patients admitted in ICU ; compared to control subjects in good health with no lung disease or global inflammation, operated under general anesthesia (i.e. intubated and ventilated) for thyroid or parathyroid.

NCT ID: NCT06249633 Not yet recruiting - Clinical trials for Pulmonary Hypertension

Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension

Start date: February 2024
Phase: Early Phase 1
Study type: Interventional

Open-label pilot study of early inhaled nitric oxide (iNO) for patients developing de novo pulmonary hypertension during Acute Respiratory Distress Syndrome (ARDS.) The study aims to determine whether iNO has possible hemodynamic and clinical benefits when given early in the course of ARDS to patients with evidence of elevated pulmonary artery pressure.

NCT ID: NCT06233448 Not yet recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Thorathic Fluid Content as an Early Predictor of Weaning From Mechanical Ventilation in Acute Respiratory Distress Syndrome

Start date: February 2024
Phase:
Study type: Observational [Patient Registry]

Thorathic fluid content measurement using indirect cardiometry is required for prediction of Weaning from mechanical ventilation in cases of acute respiratory distress syndrome and its value in sucsess Weaning

NCT ID: NCT06229821 Not yet recruiting - Clinical trials for Respiratory Distress Syndrome in Premature Infant

Safety and Efficacy of Intrapulmonary Percussive Ventilation in Preterm Infants

IPV
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the benefits and safety of Intrapulmonary Percussive Ventilation in preterm infants. IPV has been demonstrated to be safe, and improve airway secretions clearance and decreased atelectasis in pediatric patients. We aim to evaluate the effects of IPV in preterm infants.

NCT ID: NCT06212492 Not yet recruiting - Clinical trials for Moderate to Severe Acute Respiratory Distress Syndrome

Effects on Biotrauma of NMBAs and PP Association During ARDS

CURA-PRONE
Start date: February 2024
Phase: N/A
Study type: Interventional

The improved survival of patients with acute respiratory distress syndrome (ARDS) over the last decades is related to the use of so-called "protective" mechanical ventilation. Two therapies have been shown to increase survival among the most hypoxemic patients (PaO2/FiO2 < 150 mmHg): a continuous use of neuromuscular blocking agents (NMBAs) for 48 hours in the acute phase of ARDS and prone positioning (PP). NMBAs and PP are part of the latest guidelines from French ICU Society. However, North American guidelines recommend PP for patients with severe ARDS only but not NMBAs, given the results of the ROSE study which did not confirm the benefit on mortality demonstrated in the ACURASYS study. However, in the ROSE study, ventilatory strategy, use of NMBAs and PP were different from the ACURASYS study. Yet, NMBAs and PP are frequently associated in clinical practice, particularly with the COVID-19 pandemic, but also in randomized trials. In the PROSEVA study, almost all the patients (91%) received a continuous infusion of NMBAs during PP. Indeed, there is a common physiopathological rationale in both techniques: they favor the homogenization of transpulmonary pressures (TPP), reduce lung overdistension, Pendelluft effect and thus ventilator induced lung injury (VILI), in particular barotrauma and biotrauma. This reduction of biotrauma has been demonstrated for PP and NMBAs separately, but never by comparing the combined effect of the 2 techniques to each of them separately. This comparison requires reliable tools. In recent years, the "soluble form of the receptor for advanced glycation end products" (sRAGE), a new biomarker specific of pulmonary epithelial aggression and therefore of biotrauma, has been described and evaluated during ARDS and appears to be associated with the severity of pulmonary damage and prognosis. Overall, despite an interesting physiopathological rationale and a clinically widespread practice, there is currently no study evaluating the synergistic effect of PP and NMBAs in the treatment of ARDS, in particular on the prevention of VILI, and more precisely of biotrauma. This question seems crucial to better specify the respective place of each of these treatments in the management strategy of ARDS patients whose prevalence and mortality remain high. The objective of this study is therefore to evaluate, using a recent and reliable biomarker, the synergistic effect of a short-term NMBAs infusion using cisatracurium and PP on the reduction of biotrauma during moderate to severe ARDS. The investigators will compare this "synergistic" treatment to the use of PP alone. They will also evaluate, in secondary objectives, the effects of PP and NMBAs combination on clinical outcomes and on the patients' prognosis.

NCT ID: NCT06206473 Not yet recruiting - Delirium Clinical Trials

Cognitive Dysfunctions Associated With Delirium in Critically-ill ARDS Patients

DeSign
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Early cognitive assessment of critically-ill acute respiratory distress syndrome (ARDS) patients with delirium using a multidimensional electrophysiological evaluation battery (mEEG) to identify and characterize the neural correlates of cognitive dysfunctions associated with delirium (vigilance, attention, semantic and lexical processing, self-processing), and to develop a prognostic evaluation of neurocognitive and psychological disorders using an innovative non-behavioral approach.